Preserflo 微分流术的疗效、并发症和安全性

IF 0.8 4区医学 Q4 OPHTHALMOLOGY Klinische Monatsblatter fur Augenheilkunde Pub Date : 2024-09-01 Epub Date: 2024-07-24 DOI:10.1055/a-2325-9286

Cemre Altas, Thomas A Fuchsluger, Tobias Brockmann, Anna Graumüller, Marcus Walckling

{"title":"Preserflo 微分流术的疗效、并发症和安全性","authors":"Cemre Altas, Thomas A Fuchsluger, Tobias Brockmann, Anna Graumüller, Marcus Walckling","doi":"10.1055/a-2325-9286","DOIUrl":null,"url":null,"abstract":"Background: Glaucoma is a leading cause of blindness worldwide. We evaluated the efficacy, confounders, and safety of the Preserflo Microshunt over a one-year follow-up period.Methods: In this retrospective monocentric study, 111 eyes were evaluated. 83 eyes had primary open angle glaucoma, and 28 eyes secondary open angle glaucoma. Intraocular pressure (IOP), visual acuity, number of glaucoma medications, complications, and reoperations were evaluated postoperatively, at 1, 3, 6, 9, and 12 months. The influence of age, sex, type of glaucoma, previous surgery and lens status was also analysed. Bleb revision was indicated if corrected IOP exceeded 18 mmHg.Results: Intraocular pressure significantly decreased from 24.50 ± 8.94 to 14.62 ± 4.86 mmHg (4 - 32 mmHg; p < 0.001), the number of medications from 3.19 ± 1.14 to 0.98 ± 1.39 (0 - 4; p < 0.001). Confounders of interest did not affect efficacy. Bleb revision was performed in 22.5% of eyes and a cyclophotocoagulation was performed in 9.9% of eyes. Complete surgical success (IOP ≤ 17 mmHg, IOP reduction ≥ 20%, without medication) was achieved in 36.9% (n = 41) and qualified success (with medication) in 51.4% (n = 57) of eyes. Transient hypotension (≤ 5 mmHg) occurred in 19.8% after primary implantation and in 1.8% after bleb revision (duration ≤ 3 months).Conclusion: To date, the Preserflo Microshunt has demonstrated good efficacy and a low risk profile.","PeriodicalId":17904,"journal":{"name":"Klinische Monatsblatter fur Augenheilkunde","volume":" ","pages":"1048-1056"},"PeriodicalIF":0.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy, Confounders and Safety of the Preserflo Microshunt.\",\"authors\":\"Cemre Altas, Thomas A Fuchsluger, Tobias Brockmann, Anna Graumüller, Marcus Walckling\",\"doi\":\"10.1055/a-2325-9286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Glaucoma is a leading cause of blindness worldwide. We evaluated the efficacy, confounders, and safety of the Preserflo Microshunt over a one-year follow-up period.Methods: In this retrospective monocentric study, 111 eyes were evaluated. 83 eyes had primary open angle glaucoma, and 28 eyes secondary open angle glaucoma. Intraocular pressure (IOP), visual acuity, number of glaucoma medications, complications, and reoperations were evaluated postoperatively, at 1, 3, 6, 9, and 12 months. The influence of age, sex, type of glaucoma, previous surgery and lens status was also analysed. Bleb revision was indicated if corrected IOP exceeded 18 mmHg.Results: Intraocular pressure significantly decreased from 24.50 ± 8.94 to 14.62 ± 4.86 mmHg (4 - 32 mmHg; p < 0.001), the number of medications from 3.19 ± 1.14 to 0.98 ± 1.39 (0 - 4; p < 0.001). Confounders of interest did not affect efficacy. Bleb revision was performed in 22.5% of eyes and a cyclophotocoagulation was performed in 9.9% of eyes. Complete surgical success (IOP ≤ 17 mmHg, IOP reduction ≥ 20%, without medication) was achieved in 36.9% (n = 41) and qualified success (with medication) in 51.4% (n = 57) of eyes. Transient hypotension (≤ 5 mmHg) occurred in 19.8% after primary implantation and in 1.8% after bleb revision (duration ≤ 3 months).Conclusion: To date, the Preserflo Microshunt has demonstrated good efficacy and a low risk profile.\",\"PeriodicalId\":17904,\"journal\":{\"name\":\"Klinische Monatsblatter fur Augenheilkunde\",\"volume\":\" \",\"pages\":\"1048-1056\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinische Monatsblatter fur Augenheilkunde\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2325-9286\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinische Monatsblatter fur Augenheilkunde","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2325-9286","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：青光眼是全球致盲的主要原因。我们对 Preserflo 微分流术一年随访期的疗效、混杂因素和安全性进行了评估：在这项回顾性单中心研究中，我们对 111 只眼睛进行了评估。83只眼睛患有原发性开角型青光眼，28只眼睛患有继发性开角型青光眼。术后1、3、6、9和12个月对眼压（IOP）、视力、青光眼用药次数、并发症和再次手术进行了评估。此外，还分析了年龄、性别、青光眼类型、既往手术和晶状体状态的影响。如果矫正后的眼压超过 18 mmHg，则需要进行眼压计修整：结果：眼内压从 24.50 ± 8.94 mmHg 显著下降到 14.62 ± 4.86 mmHg（4 - 32 mmHg；p 结论：Preserfloor 技术是目前最有效的青光眼治疗方法：迄今为止，Preserflo 微分流术已证明疗效好、风险低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Efficacy, Confounders and Safety of the Preserflo Microshunt.

Background: Glaucoma is a leading cause of blindness worldwide. We evaluated the efficacy, confounders, and safety of the Preserflo Microshunt over a one-year follow-up period.

Methods: In this retrospective monocentric study, 111 eyes were evaluated. 83 eyes had primary open angle glaucoma, and 28 eyes secondary open angle glaucoma. Intraocular pressure (IOP), visual acuity, number of glaucoma medications, complications, and reoperations were evaluated postoperatively, at 1, 3, 6, 9, and 12 months. The influence of age, sex, type of glaucoma, previous surgery and lens status was also analysed. Bleb revision was indicated if corrected IOP exceeded 18 mmHg.

Results: Intraocular pressure significantly decreased from 24.50 ± 8.94 to 14.62 ± 4.86 mmHg (4 - 32 mmHg; p < 0.001), the number of medications from 3.19 ± 1.14 to 0.98 ± 1.39 (0 - 4; p < 0.001). Confounders of interest did not affect efficacy. Bleb revision was performed in 22.5% of eyes and a cyclophotocoagulation was performed in 9.9% of eyes. Complete surgical success (IOP ≤ 17 mmHg, IOP reduction ≥ 20%, without medication) was achieved in 36.9% (n = 41) and qualified success (with medication) in 51.4% (n = 57) of eyes. Transient hypotension (≤ 5 mmHg) occurred in 19.8% after primary implantation and in 1.8% after bleb revision (duration ≤ 3 months).

Conclusion: To date, the Preserflo Microshunt has demonstrated good efficacy and a low risk profile.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Klinische Monatsblatter fur Augenheilkunde 医学-眼科学

CiteScore

1.30

自引率

0.00%

发文量

235

审稿时长

4-8 weeks

期刊介绍： -Konzentriertes Fachwissen aus Klinik und Praxis: Die entscheidenden Ergebnisse der internationalen Forschung - für Sie auf den Punkt gebracht und kritisch kommentiert, Übersichtsarbeiten zu den maßgeblichen Themen der täglichen Praxis, Top informiert - breite klinische Berichterstattung. -CME-Punkte sammeln mit dem Refresher: Effiziente, CME-zertifizierte Fortbildung, mit dem Refresher, 3 CME-Punkte pro Ausgabe - bis zu 36 CME-Punkte im Jahr!. -Aktuelle Rubriken mit echtem Nutzwert: Kurzreferate zu den wichtigsten Artikeln internationaler Zeitschriften, Schwerpunktthema in jedem Heft: Ausführliche Übersichtsarbeiten zu den wichtigsten Themen der Ophthalmologie – so behalten Sie das gesamte Fach im Blick!, Originalien mit den neuesten Entwicklungen, Übersichten zu den relevanten Themen.